Phillips-Medisize Corporation has announced the completion of a 60,000ft2 (6,000m2) expansion project at its site in Kontiolahti, Finland.
Production has already begun on several new programmes at the site, which focuses on the industrialisation and production of inhalers, insulin pens, transfer devices and syringes. The expansion includes 12,900ft2 (1,200m2) of Class 8 clean room manufacturing and assembly, with space for additional expansion to cater for moulding machines and assembly.
New state-of-the-art, high-speed automation lines enable the ramp-up of complex, multi-component drug delivery devices from prototype to high-speed, automated, 24/7 mass production under a competitive cost structure. Total Kontiolahti capability now includes multiple, high-speed, fully automated assembly lines, fully automated printing lines and several semi-automated lines.
Since 1990, the Kontiolahti team has been serving the pharmaceutical industry with strong engineering resources, along with injection moulding and high-speed automation expertise to support complex, high-volume programmes. The in-house tooling area, coupled with experts on the pre-production team, plays a vital role in the product development and industrialisation of demanding drug delivery device projects.
Commenting on the plant expansion, Matt Jennings, president and CEO of Phillips-Medisize, stated: "The ISO 13485 multi-site, QMS-certified expansion brings our medical manufacturing square footage to over a million square feet (92,900m2), with 270,000ft2 (25,000m2) of clean room. This, coupled with extensive in-house tooling, state-of-the-art metrology, high-volume automated assembly capabilities, innovative technologies and creative people, upholds our mission to provide the highest level of satisfaction to our customers."
